MedPath

Clinical trial of 3,4-diaminopyridine(3,4-DAP) for the Lambert-Eaton myasthenic syndrome

Not Applicable
Recruiting
Conditions
ambert-Eaton myasthenic syndrome(LEMS)
Registration Number
JPRN-UMIN000029085
Lead Sponsor
Gunma university graduate school of medicine
Brief Summary

The study was terminated because the target number of participants was not reached and the study was not evaluable.

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
1
Inclusion Criteria

Not provided

Exclusion Criteria

1. serum anti-acetylcholie receptor antibody positive 2. serum anti-MuSK antibody positive 3. pregnancy 4. epilepsy 5. iver dysfunction 6. renal dysfunction 7. abnormal ECG findings 8. the patient who judged inappropriate from the doctor

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement of Manual Muscle Testing(MMT) and Hand grasping power
Secondary Outcome Measures
NameTimeMethod
Improvement of repetitive stimulation test findings
© Copyright 2025. All Rights Reserved by MedPath